Precision BioSciences (DTIL) said Monday its investigational new drug application for PBGENE-HBV in vivo gene editing program has received the US Food and Drug Administration's clearance to treat chronic hepatitis B.
The company is in final stages of US site activation to start enrolling participants in its Eliminate-B study in the country and will soon initiate phase 1 clinical activities at the Liver Center at Massachusetts General Hospital, Precision added.
The trial is already enrolling patients in Moldova, Hong Kong, and New Zealand, the company said, adding that it intends to expand the trial in the UK.
Shares of the company were up more than 7% in recent Monday premarket activity.
Price: 5.40, Change: +0.36, Percent Change: +7.14
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。